See more : Learning Tree International, Inc. (LTRE) Income Statement Analysis – Financial Results
Complete financial analysis of Chemomab Therapeutics Ltd. (CMMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chemomab Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jinan High-tech Development Co., Ltd. (600807.SS) Income Statement Analysis – Financial Results
- PT Bank Ganesha Tbk (BGTG.JK) Income Statement Analysis – Financial Results
- Skychain Technologies Inc. (SKTCF) Income Statement Analysis – Financial Results
- Omnia Metals Group Ltd (OM1.AX) Income Statement Analysis – Financial Results
- Claros Mortgage Trust, Inc. (CMTG) Income Statement Analysis – Financial Results
Chemomab Therapeutics Ltd. (CMMB)
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 66.83K | 57.77K | 34.02K | 80.00K | 281.91K | 66.00K | 51.00K | 40.64K | 26.25K | 0.00 |
| Gross Profit | -66.83K | -57.77K | -34.02K | -80.00K | -281.91K | -66.00K | -51.00K | -40.64K | -26.25K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.38M | 16.98M | 6.33M | 4.68M | 13.35M | 7.51M | 6.23M | 2.34M | 5.96M | 15.72M |
| General & Administrative | 7.08M | 11.56M | 6.03M | 1.29M | 960.00K | 374.00K | 0.00 | 0.00 | 0.00 | 5.65M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 5.96M | 5.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.08M | 11.56M | 6.03M | 1.29M | 5.98M | 5.46M | 3.11M | 2.25M | 1.14M | 5.65M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 749.00K | 3.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.46M | 28.53M | 12.37M | 5.97M | 19.33M | 12.97M | 9.34M | 4.59M | 7.11M | 21.37M |
| Cost & Expenses | 25.46M | 28.53M | 12.37M | 5.97M | 19.61M | 13.04M | 9.39M | 4.63M | 7.13M | 21.37M |
| Interest Income | 1.23M | 351.62K | 65.00 | 20.00K | 393.00K | 0.00 | 1.00K | 521.00 | 1.03K | 0.00 |
| Interest Expense | 0.00 | 353.00K | 111.08K | 6.00K | 9.00K | 0.00 | 5.00K | 0.00 | 14.16K | 0.00 |
| Depreciation & Amortization | 67.00K | 57.77K | 34.02K | 80.00K | 281.91K | 66.00K | 51.00K | 40.64K | 26.25K | 0.00 |
| EBITDA | -25.39M | -28.48M | -12.33M | -5.95M | -26.92M | -13.36M | -9.50M | -4.57M | -7.46M | 24.18M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -25.46M | -28.53M | -12.40M | -5.97M | -19.61M | -13.04M | -9.39M | -4.63M | -7.13M | 24.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.24M | 353.00K | -111.00K | 21.00K | -7.60M | -455.52K | -164.63K | 20.69K | -367.79K | 29.24M |
| Income Before Tax | -24.22M | -28.18M | -12.48M | -5.95M | -27.21M | -13.49M | -9.48M | -4.60M | -7.50M | 24.18M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -534.00K | 77.00K | -21.00K | 1.00 | 306.00K | 323.00K | 136.24K | -3.00 | 0.00 |
| Net Income | -24.22M | -27.65M | -12.56M | -5.93M | -27.21M | -13.80M | -9.81M | -4.73M | -7.50M | 24.18M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.06 | -2.43 | -1.21 | -3.20 | -15.80 | -21.84 | -217.31 | -17.42 | -32.94 | 0.00 |
| EPS Diluted | -2.06 | -2.43 | -1.21 | -3.20 | -15.80 | -21.84 | -217.31 | -17.42 | -32.94 | 0.00 |
| Weighted Avg Shares Out | 11.75M | 11.38M | 10.37M | 1.85M | 1.72M | 631.70K | 45.13K | 271.67K | 227.69K | 50.11B |
| Weighted Avg Shares Out (Dil) | 11.75M | 11.38M | 10.37M | 1.85M | 1.72M | 631.70K | 45.13K | 271.67K | 227.69K | 50.11B |
Chemomab Therapeutics Ltd (CMMB) CEO Dale Pfost on Q4 2021 Results - Earnings Call Transcript
Chemomab Therapeutics Ltd (CMMB) CEO Dale Pfost on Q4 2021 Results - Earnings Call Transcript
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
TEL AVIV, Israel, Sept. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd.
Chemomab to Participate in Upcoming September Investor Conferences
TEL AVIV, Israel, Sept. 1, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd.
Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
TEL AVIV, Israel, Aug. 13, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced financial and operating results for the...
Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
TEL AVIV, Israel and SEATTLE, June 23, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global...
CMMB Stock Price: Over 4% Increase Pre-Market Details
The stock price of Chemomab Therapeutics Ltd (NASDAQ: CMMB) increased by over 4% pre-market. These are the details.
Chemomab Therapeutics Is Heating Up And Could See A Move Soon
Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.
Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL)
TEL AVIV, Israel, June 10, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced a poster presentation at the International...
Chemomab Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update
TEL-AVIV, Israel, May 13, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced financial and operating results for the...
Chemomab to Present at Oppenheimer's Virtual Rare and Orphan Disease Summit
TEL AVIV, Israel, May 12, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the company's CEO, Dr....
Source: https://incomestatements.info
Category: Stock Reports